MOD3 Pharma

MOD3 Pharma is a Swiss biotechnology company specializing in the discovery and development of next-generation molecular glue degraders. Founded by structural biology expert Dr. Nicolas Thomä, the company leverages deep insights into protein-protein interactions to target previously undruggable proteins. MOD3 aims to create highly selective small molecules that recruit E3 ligases to degrade disease-causing targets, primarily in oncology. The company is backed by Versant Ventures and operates as part of a new wave of targeted protein degradation (TPD) firms. By utilizing high-resolution structural data, MOD3 focuses on the rational design of glues that can modulate complex biological pathways. Currently in the pre-clinical stage, the company is building a robust pipeline of therapeutic candidates for high-unmet-need indications.